OBIO 5.35 Orchestra BioMed Holdings, Inc.
| Range: | 4.22-11.69 | Vol Avg: | 65215 | Last Div: | 0 | Changes: | -0.07 |
| Beta: | 0.41 | Cap: | 0.20B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Aug 04 2020 | Empoloyees: | 56 | ||
| CUSIP: | 68572M106 | CIK: | 0001814114 | ISIN: | US68572M1062 | Country: | US |
| CEO: | Mr. David P. Hochman | Website: | https://orchestrabiomed.com | ||||
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow